Novavax, Inc.
Short

$NVAX $24 Dec 9, 2024

91
NVAX Novavax stock, $24 on 12/9/24. ctv.veeva.com/study/phase-3-study-of-the-safety-and-immunogenicity-of-covid-19-and-influenza-combination-vaccine Phase 3 trial begins on Monday, Dec. 9, 2024. Squeezing.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.